Home
  1. Miller M, Bernard L, Thompson M, Grima D, Pepin J. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol. 2010 Jul;31(7):710-5.

  2. Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord. 2010 Apr 14;11:68.

  3. Attard CL, Maroun JAA, Alloul KE, Grima DT, Bernard LM. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol. 2010 Jan;17(1):17-24.

  4. Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP. The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis. Value Health. 2009 Oct 26. [Epub ahead of print]

  5. Yoong K, Attard C, Jivraj F, Shustik C, Reece D. Cost Effectiveness Analysis of Bortezomib in Previously Untreated Multiple Myeloma Patients in Canada. Value in Health 2009; 12(7): A272

  6. Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JP, Postma MJ. Cost-effectiveness of a Prophylactic Vaccination Against Human Papillomavirus 16/18 for the Prevention of Cervical Cancer; Adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27: 4776-83

  7. Yen MS, You SL, Ferko N, Debicki D, Chen YC, Chou CY. Estimating the long-term clinical impact of cervical cancer vaccination in Taiwan. Int J Gynecol Cancer 2009 Mar-Apr; 19(2): 281-8.

  8. Ferko N, Postma M, Gallivan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 26(S) (2008): F3-F15.

  9. Gautier A, Martin-Escudero V, Moore L, Ferko N, Sanjose SD, Perez Escolano I, Catala-Lopez F, Ferrer E, Bosch FX. Long term clinical impact of introducing an HPV 16/18 ASO4 adjuvant cervical cancer vaccine in Spain. Eur J Public Health 2008 [Epub ahead of print].

  10. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L. Comparison of a detailed and succinct cohort modeling approach in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26(S) (2008) F16-F28.

  11. Grima DT, Goodman SG, Leiter LA, Attard CL, Chow CM, Langer A. How Many Cardiovascular Events Could be Prevented With Optimal Management of High Risk Canadians? Can J Cardiol. 2008 May;24(5):363-8.

  12. Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int. 2008 May;19(5):687-97.

  13. Rogoza R, Ferko N, Bentley J, Meijer CJL, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine 26(S) (2008): F46-F58.

  14. Schneider A, Hammerschmidt T, Schwartz TF, Rogoza RM, Ferko N, Siebert U. Langfristige Public-Health-Effekte einer Impfung gegen Zervixkarzinom in Deutschland (Long Term Public Health Impact of vaccination Against Cervical Cancer in Germany). Geburtshilfe und Frauenheilkunde 2007; 68: 850-8.

  15. Kohli M, Ferko N, Martin A, Franco E, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic HPV 16/18 vaccine on the burden of cervical cancer in the UK. British Journal of Cancer 2007; 96(1); 143-150.

  16. Churchill DN, Macarios D, Attard C, Kallich J, Goeree R. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract. 2007;106(4):c193-8.

  17. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and type 2 diabetes in Canada. Pharmacoeconomics. 2007;25(3):253-266.

  18. Althin R, Grima DT, Dhawan R, Bernard LM. Considerations in developing model-based economic evaluations of glaucoma treatment. J Glaucoma. 2006;15:541-547.

  19. Kohli M, Attard C, Lam A, Huse D, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815-30.

  20. Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value in Health 2006; 9(1): 54-8. In December 2006, this article was ranked as number 13 on the most read articles in Value in Health.

  21. Thompson M, Gawel M, Desjardins B, Ferko N, Grima D. An economic evaluation of rizatriptan in the treatment of migraine. Pharmacoeconomics 2005;23(8):837-50.

  22. Tingey D, Bernard LM, Grima DT, Miller B, Lam A. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Cdn J Ophthalmol. 2005 Apr;40(2):161-9.

  23. Papaioannou A, Ferko N, Clarke JA, Patterson C. Screening for Dementia. http://pier.acponline.org/ In: PIER [online database], Philadelphia, American College of Physicians, 2004.

  24. Papaioannou A, Parkinson W, Cook R, Ferko N, Coker E, Adachi JD. Prediction of falls using a risk assessment tool in the acute care setting. BMC Medicine; 2004; 2(1): 1.

  25. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG. Estimating the Prevalence of Renal Insufficiency in Seniors Requiring Long-Term Care. Kidney International 2004; 65(2): 649-653.

  26. Papaioannou A, Ferko N, Adachi JD, Watts NB. Screening for Osteoporosis. http://pier.acponline.org/ In: PIER [online database], Philadelphia, American College of Physicians, 2004.

  27. Goldie SJ, Kohli M, Grima DT, Weinstein MC, Wright TC, Bosch FX, Franco EL. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

  28. Hershorn S, Becker DL, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol. 2004 Dec;11(6):2430-7.

  29. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004 Jan;86(1):28-40.

  30. McDonald H, Hux M, Brisson M, Bernard L, Nickel JC. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol. 2004;11(4):2327-40.

  31. CE Webber, A Papaioannou, Winegard KJ, Adachi JD, Parkinson W, Ferko N, Cook RJ, McCartney N. A Six Month Home-Based Exercise Program may Slow Vertebral Height Loss. J Clin Densitometry, 2003; 6(4): 391-400.

  32. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt R, Ferko N, Puglia M, Brown J, Tenehouse A, Wojciech OP, Boulos P, Hanley DA, Josse R, Murray T, Petrie A, Goldsmith G. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis International, 2003; 14: 808-813.

  33. Papaioannou A, Adachi JD, Winegard K, Ferko N, Parkinson B, Cook R, Weber C, McCartney N. Efficacy of Home-Based Exercise for Improving Quality of Life Among Elderly Women with Symptomatic Osteoporosis-Related Vertebral Fractures. Osteoporosis International, 2003 14(8): 677-682.

  34. Papaioannou A, Parkinson W, Ferko N, Ioannidis G, Jurriaans E, Probyn L, Cox G, Stephenson G, Adachi JD. Prevalence and severity of vertebral fractures among patients with chronic obstructive pulmonary disease (COPD) in Canada. Osteoporosis International, 2003 14: 913-917.

  35. Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage. 2003 Nov;49(11):76-84.

  36. Bernard LM, Grima DT, Lam LA, Abellea S, Martin M, Dhawan R, Althin R. Clinical and economic impacts of latanoprost 0.005% in the first-line treatment of open-angle glaucoma and ocular hypertension in France. European Journal of Ophthalmology 2003, Jul;13 Suppl 4:S30-43.

  37. Goldie SJ, Grima DT, Kohli M, Wright TC, Weinstein MC, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003 Oct 10;106(6):896-904.

  38. Torrance GT, Grima DT. Demonstrating value for money of biopharmaceuticals: Health economics, regulation and reimbursement worldwide. Biotechnology Focus Magazine. Oct 2003.

  39. Papaioannou A, Bedard M, Campbell C, Dubois S, Ferko N, Heckman G, Flett N. Development and use of a computer program to detect inappropriate prescribing in older adults residing in Canadian Long term care facilities. BMC Geriatrics, 2002; 2:5.

  40. Papaioannou A, Kendler DL, Watts N, Yuen CK, Adachi JD, Ferko N. Diagnosis and Management of Vertebral Fractures in Elderly Adults. Am J Med. Jan 2002.

  41. Papaioannou A, Ray JG, Ferko N, Clarke JA, Campbell C, Adachi JD. Commentary Reply. Estimation of Creatinine Clearance in Elderly Persons in Long Term Care Facilities. Am J Med 2002; 112:684-685.

  42. Levine M, Ferko N. Commentary Reply. An Evaluation of the association between St. John’s wort and the elevation of thyroid stimulating hormone (TSH). Pharmacotherapy 2002; (In Press).

  43. Attard C, Kohli M, Coleman S, Bradley C, Hux M, Atanackovic G, Torrance GW. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002 May;186(5 Suppl Understanding):S220-7.

  44. Grima DT, Burge RT, Becker DL, Tosteson ANA. Short-term cost effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002; 27(9);448-455.

  45. Papaioannou A, Ferko N, Adachi JD. All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Pro. Inflammatory Bowel Diseases 2001; 7(2):158-162.

  46. Ferko N, Levine M. An evaluation of the association between St. John’s wort and the elevation of thyroid stimulating hormone (TSH). Pharmacotherapy, 2001; 21: 1574-1578.

  47. Papaioannou A, Ray JG, Ferko N, Clarke JA, Campbell C, Adachi JD. Estimation of Creatinine Clearance in Elderly Persons in Long Term Care Facilities. American Journal of Medicine, 2001; 111: 569-573.

  48. Tosteson ANA., Jönsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis Int. 2001;12(10):849-57.

  49. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics. 2001;19(10):1039-49.

  50. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther. 2001;23(12):2038-49.

  51. Koren G, Magee L, Attard C, Kohli M, Atanackovic G, Bishai R, Chandra K, Navioz Y, Maltepe C. A novel method for the evaluation of the severity of nausea and vomiting of pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001 Jan;94(1):31-6.

  52. Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001 Aug;47(8):36-46.

  53. Grima DT, Torrance GW, Francis G, Rice G, Rosner A, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000 Apr;6(2):91-8.

  54. Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ, Willison DJ. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics. 1998 Nov;14(5):559-73.

  55. Chiba N, Bernard L, O’Brien B, Goeree R, Hunt. A Canadian physician survey of dyspepsia management. Can J of Gastroenterol 1998;12(1):83-90.

  56. Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clinical Therapeutics. 1996; 18 (4):716-725.

  57. Coyte PC, Hawker G, Croxford R, Attard C, Wright JG. Variation in rheumatologists' and family physicians' perceptions of the indications for and outcomes of knee replacement surgery. J Rheumatol. 1996 Apr;23(4):730-8.